Discover and read the best of Twitter Threads about #TOCILIZUMAB

Most recents (24)

CAR-T en #Lupus
Dra. María Galindo
#CARTcell #SLE 🧵🩺💊💉🧪🔬
#25TenTopicsBCN #TenTopics
Resetear el sistema inmune
#Reset #immune #system
#CARTcell #SLE 🧵🩺💊💉🧪🔬
#25TenTopicsBCN #TenTopics
¿Cómo se fabrica un #CART?
#CARTcell #SLE 🧵🩺💊💉🧪🔬
#25TenTopicsBCN #TenTopics
Read 9 tweets
स्वास्थ्य सेवा महानिदेशालय #DGHS @MoHFW_INDIA द्वारा #COVID19 रोगियों के प्रबंधन के लिए व्यापक दिशानिर्देश जारी किए गए हैं जिसमें लक्षणों की गंभीरता के आधार पर रोगियों का इलाज, जांच और निगरानी कैसे करें वर्णित है।

दिशानिर्देश: dghs.gov.in/WriteReadData/…
दिशानिर्देश स्पर्शोन्मुख, हल्के, मध्यम या गंभीर लक्षणों वाले रोगियों के लिए #COVID19 के संभावित लक्षणों को वर्गीकृत करता है।

स्पर्शोन्मुख और हल्के से बीमार के लिए- घर पर अलगाव की सिफारिश की गई है।

घर पर कोविड19 को प्रबंधित करने के उपायों के लिए:
हल्के लक्षणों वाले रोगियों के लिए दिशानिर्देश में बुखार, सांस फूलना, SpO2, BP या किसी भी लक्षण के बिगड़ने के लिए स्व-निगरानी के लिए स्व-देखभाल प्रदर्शन का विवरण दिया है।

यदि लक्षण बने रहते हैं या बिगड़ जाते हैं, तो चिकित्सा जांच की आवश्यकता हो सकती है।
Read 9 tweets
Comprehensive Guidelines for Management of #COVID19 patients has been released by Director-General for Health Services (#DGHS), @MoHFW_INDIA.

Depending upon the severity of symptoms, it guides how to treat, investigate & monitor patients.

Guideline: dghs.gov.in/WriteReadData/…
The guideline categorises the possible symptoms of #COVID19 for patients with Asymptomatic, Mild, Moderate or Severe symptoms.

For Asymptomatic & Mildly ill- Home isolation for care recommended.

For Home Care Tips to manage COVID19 by @PrinSciAdvOff:
For patients with Mild Symptoms, the guideline details a #selfcare performa for Self-monitoring for fever, breathlessness, SpO2, BP or worsening of any symptoms.

If symptoms persist or worsen, further medical investigations may be required.

#COVID19 #IndiaFightsCorona
Read 9 tweets
#UttarakhandHighCourt to shortly hear PIL updating info relating to bed availability in #COVID19 hospital beds, for arranging more ICU beds in and around Dehradun, among other prayers.

Matter is before Chief Justice RS Chauhan and Justice Alok Kumar Verma.
The Court had recently issued a slew of directions pertaining to COVID-19 management in the State in this case, including fixing QR codes to #Remdesivir packets to tackle overpricing or hoarding of the drug.

Read more:

barandbench.com/news/litigatio…
The Court posts the matter on May 20th with another COVID-19 related matter. Adv Abhijay Negi seeks to make short submissions.

Court says it does not have any document that has been submitted by the State. CJ urges counsel to wait till the 20th.
Read 28 tweets
📡Live Now 📡

So you become #COVID Positive, What's Next?

For answers, watch our webinar and post if you have any other questions/doubts on #COVID19 here👉
I think there is a greater responsibility on patients too.

Doctors say, 80% effort has to be from patients. If a patient does not follow #COVID19 protocols/instructions given by Doctor, panics then it will be more difficult

- Prof. Raghuram, BITS Goa
#StayHome, do not go outside unless absolutely necessary, do not challenge the administration - it is one of the social service which we can do during this time

- Prof. Raghuram, BITS Goa

Live Now :
#Unite2FightCorona
Read 36 tweets
IMPORTANT THREAD on #COVIDTreatments - What Works & What Does not. Will be an ongoing threat.

Start with Dr Zarir Udwadia of Mumbai.
Link to Dr Udwadia's Video


1st Point: 90000+ Medical papers on Covid. UNFORTUNATELY, big divergence in Observational Studies impact and Real World impact of a rigorous RCT
RCT is Randomized controlled trial.
A Good website is Covid19Primer.com

2) What Works ?
(A) Steroids are essential. #DEXAMETHASONE 6mg/day for Critically ill Covid Patients. Reduces Death by 33/20% for Patients on Ventilators & Oxygen. ImageImageImage
Read 19 tweets
1/5
#NewAIIMSGuidelines (22.04) for #COVID19India Mangmt

Small but IMPORTANT thread for ALL.
Note : My thread is CROSS VERIFIED BY DOCTORS.
Pls amplify. 🙏

#Plasma #TOCILIZUMAB & #REMDESIVIR are NOW in EUA/Off-label usage under CERTAIN circumstances ONLY !

Pls Understand🙏
2/5
Plasma & Remdesivir benefits HAVE NO CONCLUSIVE PROOF ( Tweeted many times on this)

Don't SELF MEDICATE !
STOP RUNNING BEHIND THEM .

Instead, LEARN #Proning .Recommended by doctors also.
NOTE : THIS ACTUALLY WORKS !

Video shared
👇
3/5
Some basic pointers on #COVID19
In non medical language . I have shared my experience & some Do's and Don'ts - HOW TO WEAR MASK , WHICH MASK etc (* again cross verified by doctors)

Pls read this
👇
Read 7 tweets
Hello Navi Mumbai Folks! I have collated the below details for Navi Mumbai Resources only and sharing the same so that it can be useful (Pl Note I haven’t verified, however I have added the sources)
#BEDS #Remdesivir #Tocilizumab #OxygenCylinders #Tiffins #CovidMeals #NAVIMUMBAI
#Beds Availability #NaviMumbai Only:
covidbedpanvel.in/HospitalInfo/s…
nmmchealthfacilities.com/HospitalInfo/s…
(*Please visit the site to check real time Beds availability / कृपया वास्तविक समय की जाँच के लिए साइट पर जाएँ / रिअल टाईम बेड उपलब्धता तपासण्यासाठी कृपया साइटला भेट द्या*)
Read 5 tweets
I know the #COVID-19 numbers in India are not looking good, but here are my (not so) random thoughts on it Image
We have 2 options – one, rant & rail against the ‘system’ and lament how it has let us down; second, do whatever we can to avoid getting infected & if infected, minimize adverse consequences to ourselves & others. If you belong to the first, you can stop reading now
How can we avoid getting infected? There’s no magic bullet, I’m afraid. This is primarily a “stick to the basics” approach. More difficult than it sounds.
Read 25 tweets
This is the Nationwide Distributor List for #Remdisivier

Sharing this so it can help those who need it 🙏🏼

List is sorted by distributor name in alphabetical order.
Read 11 tweets
Thread: #Lucknow #COVID RESOURCES
Plasma Donors :

Please refer to this page:
instagram.com/plasmadonor.lu…
Remdevsir:

1.
@itsmesabita

- please DM her
2. Cipla Med Gautam Enterprise - 9868124105
3. Mitesh Shah - He is not a supplier, he is finding the injection on demand as a social cause, and he was helpful

I request you to only text and not call them.
Read 19 tweets
Why is there a shortage of Remdesivir, with family members desperately trying to procure it when it has been proven that it is no better than routine care? #EvidenceBasedMedicine
There are two living meta analysis and systematic reviews that show it is not better than routine care. Close to 4000 patients in randomized trials showing no benefit, and patients & families desperate and buying in the black market because they believe it will save their patient
Wow! This tweet seems to have stirred up a lot of interest (and violent reactions). I'm glad there has been (some) discussion about the science, and the evidence, and justifiable disagreement. We've had experienced experts in the field weighing in, and I respect those views
Read 19 tweets
Following @remap_cap & #RECOVERY #Tocilizumab results, @NIHCOVIDTxGuide has updated guidelines:
-#Toci + #Dexamethasone now recommended for all ICU pts on IMV, NIPPV, or HFNC
-Toci + Dex recommended for non-ICU pts w/ rapidly increasing O2 needs & elevated inflammatory markers
1/
You can read the updated NIH COVID19 treatment guidelines here: covid19treatmentguidelines.nih.gov/statement-on-t…

IMO, this change makes sense based on the published & pre-published data, which I discussed last month:
2/
There are some caveats:
-Toci must be combined with dexamethasone (not given alone; ? harm signal)
-It should be given early (w/i 3 days)
-Toci should NOT be given to people who are already immunosuppressed or who have “an uncontrolled” infxn (e.g. getting worse despite Abx)
3/
Read 5 tweets
El 11 de febrero se conocieron los resultados del ensayo #Recovery, el mayor realizado hasta ahora, que demostró que el uso de #Tocilizumab disminuye el riesgo de muerte en pacientes con Covid-19 que requieren apoyo con oxígeno. Pero... 🧵

🧪bit.ly/2ZbsJqD Image
se trata de un fármaco de alto costo en monopolio, cuya patente la tiene #Roche. En Perú, al inicio de la pandemia muchas familias intentaron cubrir esta terapia (cada ampolla cuesta 3 mil soles) endeudándose. @essalud y @Minsa_Peru las compraron a distintos precios. Image
#Tolicizumab actúa en un momento específico en la evolución de la enfermedad en el que la persona agrava sus síntomas rápidamente. Se denomina "tormenta de citoquinas". Este medicamento actúa como un inhibidor de citoquinas y podría detener dicha "tormenta". Image
Read 5 tweets
🚨Exciting results from the #RECOVERY trial #preprint of #Tocalizumab (Toci) in hospitalized people w/ #COVID19
-reduced 28-day mortality (29 vs 33%; NNT)
-decreased likelihood of requiring MV (33% vs 38%)
-shorter hospital stay (median 20 vs >28 days)
medrxiv.org/content/10.110…
1/
They randomized 4116 pts to weight-based Toci vs usual care (UC):
-groups were balanced: mostly male (>65%), older (>60 yo), & w/ comorbidities (>55%)
-most patients (82%) also received dexamethasone
-they received Toci early in hospitalization but were 7-14 days after onset
2/
Notably, only 83% of patients in the Toci group actually received Toci (plus 2.6% randomized to the UC group got Toci); this would decrease the effect size and bias the towards null.

This means their ITT analysis is probably *underestimating* the true effect size somewhat.

3/
Read 13 tweets
Anti IL-6 en pacientes críticamente enfermos con Covid-19 - Informe preliminar.

Investigadores de REMAP-CAP.

medrxiv.org/content/10.110…
El ensayo muestra que los pacientes que reciben tocilizumab y un segundo fármaco : sarilumab, pueden reducir el riesgo relativo de muerte en un 24% cuando se administran a los pacientes dentro de las 24 horas posteriores al ingreso en cuidados intensivos.
Los pacientes tienen un impacto significativo en la supervivencia.
nihr.ac.uk/news/arthritis…
Read 14 tweets
@remap_cap is proud to announce the findings of IL-6 blockade in critically ill patients with #COVID19.
medrxiv.org/cgi/content/sh… (1/10)
353 patients randomized to #tocilizumab, 48 to #sarilumab, and 402 to control.
Adjusted odds ratio for improvement on organ-support free days at day 21 was 1.64 (CrI 1.25 - 2.18) and 1.89 (1.24 - 3.48), respectively. (2/10)
Mortality was 28% with tocilizumab, 22.2% for sarilumab (combined 27.3%), and 35.8% for control, with benefit of IL-6 blockade on all secondary outcomes collected. (3/10)
Read 10 tweets
Some interesting news here from @remap_cap that #Tocilizumab may improve patient outcomes for COVID-19. Understandable that the team are eager to announce this but given the limited detail and small sample of 303 patients, a few notes of caution are needed.... 1/7
The researchers have declared #Tocilizumab has 'efficacy' for a combination of patient outcomes which include survival and how long patients spend on organ support eg a ventilator. Efficacy means the drug can work in specific (usually well controlled) circumstances. 2/7
It looks like there is a big treatment effect (odds ratio: 1.87) in this trial. That's great but results like this are sometimes too good to be true. Treatment benefits are generally smaller in large trials which account for the real-world problems of delivering patient care. 3/7
Read 8 tweets
Por recomendación de la junta de monitoreo y seguridad de datos, @REMAP_CAP está declarando la eficacia de #tocilizumab con un OR de 1.87 p/beneficio de combinación de supervivencia y tiempo que los ptes recibieron soporte orgánico en UCI, en comparación c/atención estándar ...
Este hallazgo tiene un alto grado de certeza estadística, con un 99,75% de probabilidad de beneficio del tocilizumab en comparación con la ausencia de modulación inmunitaria
Esta conclusión se basa en los primeros 303 pacientes críticamente enfermos asignados al azar
Read 5 tweets
On the recommendation of the data safety and monitoring board, @REMAP_CAP is declaring efficacy of #tocilizumab with an OR of 1.87 for benefit on a combination of survival and length of time patients received organ support in ICU, compared with standard care [...]
This finding has a high degree of statistical certainty, with 99.75% probability of benefit for tocilizumab compared to no immune modulation […]
This conclusion is based on the first 303 critically ill patients randomized in the #COVID19 immune modulation domain; due to rapid recruitment since that interim analysis, the final analysis will have hundreds more patients included [...]
Read 9 tweets
Excited to share our publication on #inflammation, #metabolic dysregulation, & #depression symptoms now out @JAMAPsych!

This is work by @Binder_Lab, Janine Arloth, @mgeorgakis1, @and_Ramses_II, Symen Ligthart, & @golam_khandaker.

Tweetorial below

jamanetwork.com/journals/jamap…
In this project we studied symptom heterogeneity in #depression, which is highly prevalent and may hamper ongoing research efforts in depression. @caina89, @karmelchoi, & @EikoFried have recently conducted an excellent review on the genetic side of this:
academic.oup.com/hmg/article/29…
In our study, we focused on the association of #inflammation w/ specific depressive symptoms, which was previously largely described in cross-sectional studies, but also some longitudinal & polygenic risk score work.
Read 14 tweets
#NewsApp Actualizamos toda la evidencia que hasta ahora se conoce sobre los tratamientos contra el COVID-19 con el gran aporte de @EpistemonikosEs. Hoy también encontrarán novedades: la #Hidrocortisona [Hilo]

saludconlupa.com/comprueba/cien…
Ahora sabemos la #hidrocortisona, un corticoide al igual que dexametasona, funciona para el tratamiento de casos graves de COVID-19 (aquellos que requieren atención en unidades de cuidados intensivos). La OMS recopiló los resultados de todos los ensayos que lo confirman.
Las nuevas revisiones permiten conocer también que #tocilizumab, #sarilumab y #azitromicina bajaron su clasificación de evidencia y son ahora poco prometedores como terapia COVID-19.

👨‍🔬👩‍🔬🧪saludconlupa.com/terapias-covid…
Read 3 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!